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mainly by the presence of osteophytes and thinning of joint
cartilage.
To examine by serum molecular markers the response of bone
tissue in early stage knee OA.
Methods: The study group consisted of 147 subjects aged 32-
55 (mean 45) years (51 male, 96 female) with chronic knee
pain. Half of the female subjects studied were postmenopausal.
Altogether 20 and 32 female subjects matched by age and place
of residence served as controls.
Bilateral radiographs were graded for tibiofemoral(TF) and
patellofemoral(PF) knee OA at baseline and in the 3 year follow-
up. At baseline, 55(34%) individuals in the study group had knee
joint symptoms but no radiographic findings, 85(53%) were diag-
nosed with knee OA grade I. Twenty-one subjects (13%) had OA
grade II or III, predominantly in the PF region. Radiographic find-
ings of osteophytes and JSN were distributed in the OA group as
follows: one-third had only osteophytes, another third had only
JSN and the rest had both simultaneously.
At baseline a general marker of bone turnover, serum osteocal-
cin (S-OC) and propeptide of type I procollagen (S-P1NP) were
measured. At baseline and 3 years later validated bone resorp-
tion marker serum C-terminal cross-linked telopeptides of type I
collagen (S-CTx-I) was assessed by ECLIA (Roche Diagnostics).
Statistics: non-parametric methods.
Results: All three markers revealed significant gender differ-
ences. S-CTx-I levels were significantly higher in men. Medians
for CTx-I for men and women were 0.416 and 0.371 ng/ml
(p=0.033). S-OC levels were higher in women (medians for
men and women 18.6 and 22.6 ng/ml, p=0.012). S-P1NP levels
trended to be higher in women (p=0.08). CTx-I and P1NP levels
were significantly higher in female postmenopausal symptomatic
subjects compared to female controls.
We were not able to demonstrate significant correlations between
knee OA scores and bone markers neither in men nor women.
However, in women we observed an association between base-
line S-OC and presence of osteophytes localizing in any knee
joint compartment (rho=0.228, p=0.034). More detailed analy-
sis revealed a correlation between S-OC and TF osteophytes
in lateral compartments in premenopausal subjects (rho=0.327,
p=0.032).
The same was observed with baseline P1NP (but not with base-
line CTx-I) that correlated with TF osteophytes in lateral com-
partments (rho=0.269, p=0.045) in women.
In women, S-CTX-I levels were significantly correlated with height
and S-OC with age. In men, we did not find an association be-
tween knee joint osteophytes and bone markers, but all markers
correlated with BMI.
Conclusions: 1. Gender differences have an important effect
on the levels of bone markers. Postmenopausal women have
significantly increased bone turnover.
2. In case of early knee OA bone turnover is accelerated. In-
creased synthesis of type I collagen seems to refer to the
proliferative bone response expressed by osteophytes.
3. Baseline S-OC and S-P1NP levels seem to have predictive
value for definite type of osteophytosis some years later.
4. For interpretation of the results of bone markers one has to
consider the important contribution of age, gender and BMI.
P94
NITROSYLATED N-TELOPEPTIDE OF TYPE III
COLLAGEN (IIINYS): A NEW SPECIFIC BIOCHEMICAL
MARKER OF OXIDATIVE-INDUCED SYNOVIAL TISSUE
METABOLISM IN ARTHRITIS
N. Charni1, P. Richardot1, A.B. Jensen2, J.-M. Delaissé2,
P. Garnero3
1Molecular Markers, SYNARC, Lyon, France, 2Clinical Cell
biologi, Vejle Hospital, Vejle, Denmark, 3SYNARC and INSERM
U664, Lyon, France
Purpose: Nitric oxide (NO) is an important mediator of joint
inflammation and destruction in rheumatoid arthritis (RA) and
osteoarthritis (OA). Peroxynitrite induced by NO can react with
amino acids including tyrosine (Y) to form nitrotyrosine. Increased
NO-related species have been found in the joint of patients with
OA or RA, especially in synovial tissue. The aim of this study
was to develop an immunoassay recognizing nitrosylated N-
telopeptide of type III collagen - one of the main constituent of
synovial membrane - to monitor oxidative-related joint damage
in arthritis.
Methods: We produced a polyclonal antibody raised against a
nitrosylated sequence specific of the N-telopeptide of human
type III collagen (IIINys). Using IIINys antibody, we performed
immunohistochemistry of synovial tissue from 11 patients with
knee OA undergoing total joint replacement. We also developed
a competitive ELISA to measure IIINys levels in the synovial fluid,
serum and urine of healthy controls and patients with OA or RA.
Results: The IIINys antibody did not recognize the non-
nitrosylated sequence of type III collagen N-telopeptide, nitro-
sylated BSA and free nitrotyrosine, indicating high specificity
for both nitrosylation and type III collagen sequence. Immuno-
histochemistry of synovial tissue from patients with knee OA,
showed strong IIINys staining in the extracellular matrix, particu-
larly around the synoviocytes and within macrophage-like cells.
The ELISA for serum IIINys demonstrated intra and inter-assay
CV below 15% and recovery of diluted serum samples ranged
from 96.6 to 118.3% (mean: 99%). Detectable levels of IIINys
were measured in the synovial fluid, serum and urine of 11 pa-
tients with knee OA. Compared to 30 healthy postmenopausal
women, serum IIINys levels were increased by an average of
195% (p<0.0001) in 30 postmenopausal women with early RA.
Conclusions: We have developed an immunoassay which de-
tects specifically nytrosylated type III collagen N-telopeptide (II-
INys). The strong immunoreactivity of IIINys in the synovial tissue
of patients with OA and the marked increased serum IIINys levels
in patients with RA, suggest that this new biochemical marker
should be useful for the investigation of oxidative-induced alter-
ations of synovial tissue in patients with RA or OA.
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Purpose: The importance of bone turnover is increasingly rec-
ognized in osteoarthritis (OA) pathogenesis.Lead (Pb) is a heavy
metal that affects many aspects of bone including osteoclasts,
osteoblasts, and calcium and vitamin D metabolism. As such,
Pb could potentially be involved in OA given the importance of
bone in this process. The effect of Pb on cartilage and other joint
tissues is not known. No previous studies have evaluated effects
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of lead on putative OA biomarkers. We examined whole blood Pb
levels and OA biomarkers in African American and white women.
Methods: A total of 339 women in the Johnston County OA
Project Metals Exposure Sub-study (mean age 62.5 (9.4) years,
35% African American) had available whole blood, serum, or
urine samples for whole blood lead and biomarkers assessments.
Whole blood lead was measured by inductively coupled plasma
mass spectrometry at the Inorganic Toxicology laboratory, Divi-
sion of Laboratory Sciences, National Center for Environmental
Health, CDC, Atlanta, Georgia. Urine C-telopeptide fragments
of type II collagen (CTX-II), cross linked N telopeptide of type
I collagen (NTX-I), serum hyaluronic acid (HA) and cartilage
oligometric matrix protein (COMP) were measured by commer-
cially available kits. Radiographic knee OA (rKOA) was defined
by Kellgren-Lawrence grades (2-4) with fixed-flexion posterior-
anterior knee films. Pearson correlation coefficients were calcu-
lated between Log Pb and log of each biomarker. Analysis of
covariance models were used to examine associations between
blood lead levels and the 4 chosen biomarkers with log trans-
formed biomarkers as outcomes, adjusted for age, race, BMI,
and rKOA variables. Effect modification between log Pb and race
were examined, with significance defined by p-values < 0.1 for
interaction terms.
Results: Median Pb levels were 1.9 ug/dL (0.5-25.4) and were
higher in African American women than white women (p <
0.001). In bivariate associations, log Pb was correlated with log
CTX-II (r=0.14, p=0.009) and log NTX-I (r=0.22, p<0.0001), but
not with log COMP or log HA (r= 0.07 and 0.06, respectively,
p>0.20). In adjusted models, log Pb was associated with mean
log CTX-II (p = 0.007), NTX-I (p <0.001), and COMP (p = 0.036),
but not with mean log HA (p = 0.9). There were no notable race
and log Pb interactions.
Conclusions: Mean blood Pb levels are associated with urine
CTX-II, urine NTX-I, and serum COMP, but not serum HA in both
African American and white women. These data suggest that
Pb has an effect not only on bone collagen, but also on type II
collagen and non-collagenous matrix proteins. Potential effects
of Pb in the pathogenesis of OA, then, are likely to be related
to alterations in these factors, but not to effects on synovial
inflammation. We are planning further studies to delineate how
Pb may affect joint structures and how other factors such as
menopause, hormone replacement therapy, and bone density,
might influence these associations.
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Purpose: Data from a meta-analysis of randomized controlled
trials suggest that 1 g of naproxen is not associated with dele-
P96 – Table 1. Percent Inhibition of Serum Thromboxane (TXB2) trough/steady state*
Period 1 Period 2 (EC-ASA 81mg) Period 1 - Period 2 Lower Limit Non-inferiority (5%)
Mean (SD) Mean (SD) Mean Difference(SD) One-sided 95% CI
NAPSO 220 mg bid (440 mg) (n=11) 97.9 (3.20) 98.4 (2.54) -0.5 (2.20) -1.7
NAPSO220 mg tid (660 mg) (n=9) 99.4 (0.77) 98.0 (2.57) 1.3 (2.46) -0.2
NAPSO550 mg bid (1100 mg) (n=11) 99.6 (0.69) 97.2 (5.65) 2.3 (5.46) -0.6
Placebo (n=10) 47.3 (41.03) 99.2 (1.01) -51.9 (41.18) -75.8
*Blood drawn 24 hrs after last ASA dose and 12 hrs after last NAPSO dose at steady state
terious cardiovascular outcomes, perhaps due to its antiplatelet
effects. The effect of over-the-counter (OTC) doses of naproxen
on platelets is unknown. We compared the antiplatelet effects
of OTC doses of naproxen sodium (NAPSO) with a prescrip-
tion (Rx) dose of NAPSO and low-dose enteric-coated aspirin
(EC-ASA).
Methods: Single-center, randomized, open-label, placebo-
controlled, 2-period crossover trial in healthy male and female
subjects. Subjects were administered 1 of 3 regimens of NAPSO
(NAPSO 220 mg twice daily (bid), NAPSO 220 mg 3 times daily
(tid), or NAPSO 550 mg bid) or placebo for 7 days. After a
washout period of at least 6 days, subjects were crossed over
to receive EC-ASA 81 mg once daily for 7 days. The primary
endpoint was inhibition of serum thromboxane B2 (TXB2), mea-
sured at trough (12 hours after the final dose of NAPSO) and 24
hours after final dose of EC-ASA. Inhibition of serum TXB2 was
measured by a commercially available enzyme immunoassay.
Results: A total of 48 subjects were randomized [the intent-
to-treat (ITT) population], and 41 (11 NAPSO 220 mg bid, 9
NAPSO 220 mg tid, 11 NAPSO 550 mg bid, 10 placebo) met
the criteria for the evaluable population. Baseline characteristics
were comparable among the 4 groups. NAPSO demonstrated
an aspirin-like effect on platelet aggregation, as measured by
inhibition of serum TXB2. The mean (±SD) degree of serum
TXB2 inhibition was 97.9% (± 3.20%) for NAPSO 220 mg bid
and 99.4% (± 0.77%) for NAPSO 220 mg tid. The inhibitory
effects of these OTC doses of NAPSO were similar to the Rx
dose of NAPSO 550 mg bid [99.6% (± 0.69%)]. The lower limit
of a one-sided 95% CI test for non-inferiority (NAPSO or placebo
versus ASA) for each treatment was -1.7% for NAPSO 220 mg
bid, -0.2% for NAPSO 220 mg tid, -0.6% for NAPSO 550 mg bid,
and -75.8% for placebo (Table 1). All doses of NAPSO were not
inferior to EC-ASA 81 mg. Results were confirmed in an analysis
of the ITT population.
Conclusions: Over-the-counter doses of NAPSO produced an
antiplatelet effect similar to low dose EC-ASA and Rx dose
NAPSO, as measured by inhibition of serum TXB2.
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Purpose: Inter-α-trypsin Inhibitor (IαI) occurs in plasma and
has protease inhibitory activity. Heavy chains of IαI can bind
covalently to hyaluronan (HA) to form a serum derived hyaluro-
nan associated protein, SHAP, releasing bikunin. The transfer
of IαI heavy chain to HA is catalyzed by enzyme factors such
as TNFα-stimulated gene 6 protein (TSG-6). SHAP potentiates
CD44-mediated leukocyte adhesion to hyaluronan substratum,
and has putative roles in HA cross-linking and inflammation.
